A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Registration Number
- JPRN-jRCT2080222069
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
The study will enroll men or nonfertile women, at least 50 years of age with evidence of memory impairment on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR), a Mini-Mental State Examination (MMSE) 16 to 30, no history of macrohemorrhage and no more than 4 microhemorrhages on magnetic imaging resonance (MRI), and a positive amyloid scan by florbetapir. Patients with contraindication for MRI, presence of >4 microhemorrhages on MRI, history or evidence on MRI of macrohemorrhage will be excluded.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method